Cross-Over Study of Sevelamer Hydrochloride and Sevelamer Carbonate

Inclusion Criteria: * patient had received hemodialysis three times per week for 3 months or longer; * patients were maintained on sevelamer hydrochloride as their primary phosphate binder with a total daily dose of ≤ 13.6 g with serum phosphorus concentrations at the last two measurements between 3.0 and 6.5 mg/dL, the most recent iPTH ≤ 600 pg/mL and the most recent serum calcium within the normal range. Exclusion Criteria: * if patient had active bowel obstruction, dysphagia, swallowing disorders, or severe gastrointestinal motility disorders; * active ethanol or drug abuse (excluding tobacco); * need for antidysrhythmic or antiseizure medications used to control these conditions; * poorly controlled diabetes mellitus or hypertension; * active vasculitis; * active malignancy other than basal-cell carcinoma; * HIV infection; or * any clinically significant unstable medical condition as judge by the Investigator.